We won 1st prize – again! 🏆
At the prestigious BioRegio STERN Ideenwettbewerb 2025, dxOmics was awarded first place for our innovative approach to AI-driven genome diagnostics. The jury recognized our cloud-based software for its ability to translate complex sequencing data into actionable treatment decisions for rare diseases and cancer – a solution already implemented in German hospitals and fully reimbursable by health insurance.
dxOmics wins 1st place at the BW Start-up Summit!
We are honored to have received the 1st prize at the BW Start-up Summit – thank you to Start-up BW Summit, Nicole Hoffmeister-Kraut, and THE LÄND for this recognition!
Our AI-powered diagnostics platform for rare diseases, cancer, and pharmacogenetics stood out in a highly competitive field – a strong signal for the growing importance of personalized genomic medicine.
dxOmics GmbH at NVIDIA GTC 2025 !!! – AI in Genomic DiagnosticsWe are excited to share that Stephan Ossowski, Co-Founder and CSO of dxOmics, will be attending the NVIDIA GTC AI Conference from March 17–21 in San Jose, CA.dxOmics is at the forefront of hashtag#AI-driven genomic diagnostics, providing hospitals and genetic testing labs with cutting-edge solutions for cancer and rare disease diagnostics. Our platform integrates long-read sequencing, AI-powered variant interpretation, and automated clinical reporting, ensuring highly accurate and scalable molecular diagnostics. With over 50,000 patient datasets analyzed, our AI-driven approach accelerates hashtag#precisionmedicine and supports clinical decision-making.At hashtag#GTC25, we are eager to explore new AI applications in genomics, hashtag#cloud-based diagnostics, and potential collaborations. If you’re attending and would like to connect with @Stephan Ossowski, feel free to PM us.
Linkedin Post
dxOmics presents at Oxford Nanopore London Calling 2025
On our way to Oxford Nanopore Technologies ONTLC25. We are
presenting our latest results on AI-assisted clinical decision support for
long-read diagnostics at London Calling
2025. The platform, developed at the University Hospital TĂĽbingen and its
spin-out dxOmics , is DAkkS-accredited and used in routine long-read
diagnostics for rare diseases and cancer. Meet Stephan Ossowski (Wed–Thu) and
Daniela Bezdan (Wed–Fri) in London.